Introduction/Background Gynaecological cancers are the second most common cancers in the female population. Timely diagnosis is important in improving survival outcomes for ovarian cancer as delays in receiving first treatment can result in higher stage at diagnosis leading to higher levels of non standard treatment or no treatment. The number of patients referred with suspected cancer symptoms continues to rise putting more pressure on rapid access services working at full capacity to meet nationally agreed cancer diagnosis targets across the UK. There is an urgent demand for more efficient cancer pathway developments to prevent delays in ovarian cancer diagnosis. We present a comparison of our cancer target outcomes following the introduction of a straight to test pathway for patients presenting with symptoms suggestive of ovarian cancer.

Methodology Data was collected retrospectively from electronic patient records on patients attending rapid access services with symptoms suggestive of ovarian cancer/raised CA125 and time to diagnosis calculated.

Results 403 patients attended rapid access services during October 2019 and December 2019. 63 of these patients had suspected ovarian cancer symptoms. 30 of these patients required further imaging for diagnosis. 23 out of 30 patients received their diagnosis within recommended targets. (76%). Average time to diagnosis was 4–36 days.

Following the introduction of the new triage system 565 patients were seen in clinic from December 2022 to February 2023. 78 patients had symptoms suggestive ovarian cancer and 25 of these patients were identified as high risk and were sent straight for diagnostic testing. Progressive improvement in time to diagnosis was seen in comparison to previous data.( 55% December, 81% January, 100% February).

Conclusion Introduction of the new triage system to identify high risk patients likely to need further diagnostic testing for suspected ovarian cancer from date of referral shortens time to diagnosis allowing patients to receive timely treatment for ovarian cancer.

Disclosures None